This program is supported by an independent education grant from Pfizer Global Medical Grants. This online education program has been designed for healthcare professionals globally.
In this virtual 45-minute Grand Rounds session, leading expert Dr Sarah Sammons, MD explores advanced sequencing and shared decision-making strategies in HER2-positive metastatic breast cancer. Dr. Sammons will:
- Evaluate multi-drug maintenance strategies, including the latest evidence for adding TKIs and ADCs, balancing efficacy endpoints, CNS benefits, and toxicity considerations
- Apply patient-centred, quality-of-life–focused decision-making through real-world case vignettes, matching regimen intensity to tumour biology, CNS risk, comorbidities, and patient preferences .
- Synthesize and map current guideline recommendations and emerging trial data to clarify decision points from induction through maintenance and later-line transitions .
Accreditation: 0.75 AMA PRA Category 1 Credits™
Session Highlights
- Maintenance strategies: Examine TKI vs ADC selection and sequencing, with practical dosing and toxicity-management guidance.
- Patient-centred decision-making: Utilize shared-decision tools and case examples to personalize regimens based on tumour biology and patient goals.
- Evolving guidelines & evidence: Integrate the latest consensus recommendations and trial findings to optimize 1L and maintenance care pathways.
Who Should Watch
- Medical Oncologists
- Nurse Practitioners
- Physician Assistants
- Oncology Nurses
- Oncology Fellows
- Pharmacists
- Internal Medicine Physicians with an Oncology Focus
- Other HCPs involved in MBC care
Presented by
Dr Sarah Sammons, MD – is a medical oncologist specializing in breast cancer, with a focus on metastatic disease and brain metastases. She has led clinical trials that have advanced treatment options for metastatic breast cancer. She was previously Associate Director of Breast Cancer Research at Duke Cancer Institute and, since 2022, serves as a medical oncologist and Associate Director of the Metastatic Breast Cancer Program at Brigham and Women’s and Dana-Farber.
We thank our patient contributor, who is working in advocacy and collaboration with Living Beyond Breast Cancer.
Continuing Education Information
Commercial support: This activity received monetary support through an independent education grant from Pfizer
Disclosures
Dr Sarah Sammons has disclosed financial relationships within the past 24 months with the following ineligible companies: Daiichi Sankyo, Relay Therapeutics, Seagen, Sermonix, AstraZeneca, Gilead, Eli Lilly, Incyclix, Pfizer, and Novartis. These relationships include research funding and consulting/advisory roles.
These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Sammons intends to discuss non-FDA uses of drug products and/or devices only in relation to products for which she has no financial relationships. She will disclose to the audience when this discussion takes place.
AffinityCE staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.
Activity Accreditation for Health Professions
This activity will be planned and implemented in accordance with the accreditation requirements and policies of both the Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). Through joint providership with AffinityCE (ACCME-accredited) and MedAll (EBAC-accredited), continuing education credit will be provided for both live and enduring activities.
EBAC Compliance and Credit Conversion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of EBAC.
In compliance with EBAC guidelines, all speakers and chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 0.75 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website at https://edhub.ama-assn.org/pages/applications. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 0.75 Credit™.
The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.
How to Earn Your CME Credit
In order to obtain your CME credit and receive your certificate, please join the webinar and complete the assessment at the end. You will receive a link to your certificate automatically after completing the assessment.
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Participation Costs
There is no cost to participate in this program.
ACCME Continuing Education Information
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures will be declared prior to the event.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™.
Physician Assistants
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring activity a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Pharmacists
Pharmacists AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).
Session 2: Optimizing Maintenance in HER2+ Metastatic Breast Cancer - Live
Format: Live Portion
UAN: 0829-9999-25-171-L01-P
Activity Type: Knowledge-based
CEUs: 0.75
No cost to participate.
Participant CE records will be electronically communicated to CPE Monitor.
Pharmacist Learning Objectives
At the conclusion of this web conference, participants should be able to:
At the conclusion of this web conference, participants should be able to:
- Evaluate multi-drug maintenance strategies including TKIs and ADCs
- Apply patient-centred, QoL-focused decision-making to personalize maintenance regimens.
- Evaluate guidelines and latest evidence to understand the treatment paradigm and 1-L standard of care evolution for patients with HER2+ MBC
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program
Unapproved and/or off-label use disclosure
AffinityCE/MedAll requires CE faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Participation Costs
There is no cost to participate in this program.